Supernus Pharmaceuticals Inc (SUPN)
Interest coverage
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 81,666 | -1 | 46,124 | 92,871 | 188,083 |
| Interest expense | US$ in thousands | — | 1 | 7,070 | 19,696 | 19,435 |
| Interest coverage | — | -1.00 | 6.52 | 4.72 | 9.68 |
December 31, 2024 calculation
Interest coverage = EBIT ÷ Interest expense
= $81,666K ÷ $—K
= —
The interest coverage ratio for Supernus Pharmaceuticals Inc has shown some fluctuations over the years. As of December 31, 2020, the interest coverage ratio stood at 9.68, indicating that the company was generating sufficient earnings to cover its interest expenses comfortably. However, by December 31, 2021, the ratio declined to 4.72, suggesting a decrease in the company's ability to cover its interest obligations with its earnings.
In the following year, as of December 31, 2022, the interest coverage ratio improved to 6.52, signaling a partial recovery in the company's ability to pay its interest expenses. However, a concerning trend emerged by December 31, 2023, where the interest coverage ratio fell to -1.00. A negative interest coverage ratio indicates that the company's earnings were insufficient to cover its interest payments, raising concerns about its financial health.
Unfortunately, the data for December 31, 2024 is unavailable (marked as dash), making it challenging to assess the current status of Supernus Pharmaceuticals Inc's interest coverage ratio. Overall, the fluctuating trend in the interest coverage ratio highlights the importance of closely monitoring the company's financial performance and its ability to meet its debt obligations from its operational earnings.
Peer comparison
Dec 31, 2024